Samsung Bioepis Co. Ltd., of Incheon, Korea, said its marketing authorization application for SB3, a biosimilar candidate referencing Herceptin (trastuzumab, Roche Holding AG), a monoclonal antibody indicated for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer, has been accepted for review by the EMA.